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Increased VEGF-A promotes multiple distinct aging
diseases of the eye through shared pathomechanisms
Alexander G Marneros1,2,*
Abstract
While increased VEGF-A has been associated with neovascular
age-related macular degeneration (AMD), it is not known whether
VEGF-A may also promote other age-related eye diseases. Here, we
show that an increase in VEGF-A is sufficient to cause multiple
distinct common aging diseases of the eye, including cataracts and
both neovascular and non-exudative AMD-like pathologies. In the
lens, increased VEGF-A induces age-related opacifications that are
associated with ERK hyperactivation, increased oxidative damage,
and higher expression of the NLRP3 inflammasome effector
cytokine IL-1b. Similarly, increased VEGF-A induces oxidative stress
and IL-1b expression also in the retinal pigment epithelium (RPE).
Targeting NLRP3 inflammasome components or Il1r1 strongly
inhibited not only VEGF-A-induced cataract formation, but also
both neovascular and non-exudative AMD-like pathologies. More-
over, increased VEGF-A expression specifically in the RPE was
sufficient to cause choroidal neovascularization (CNV) as in
neovascular AMD, which could be inhibited by RPE-specific inacti-
vation of Flk1, while Tlr2 inactivation strongly reduced CNV. These
findings suggest a shared pathogenic role of VEGF-A-induced
and NLRP3 inflammasome-mediated IL-1b activation for multiple
distinct ocular aging diseases.
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Introduction
The VEGF-A gene locus has been associated with both neovascular
(“wet”) and non-exudative (“dry”) age-related macular degenera-
tion (AMD) (Yu et al, 2011; Fritsche et al, 2013). VEGF-A is also
increased in aqueous humor samples from eyes of patients with
neovascular AMD, and a direct pathogenic role of increased VEGF-A
is supported by the observed clinical benefit of anti-VEGF-A thera-
pies that can inhibit further progression of neovascular AMD (Funk
et al, 2009; Group et al, 2011). However, chronic use of anti-VEGF-A
antibodies can show diminished therapeutic activity with disease
progression of neovascular AMD and may induce adverse side
effects in the retina, likely by inhibiting neuroprotective functions of
VEGF-A or by impairing the choriocapillaris that requires VEGF-A
for its maintenance (Marneros et al, 2005; Rofagha et al, 2013).
Thus, novel treatment options are needed that target downstream
pathways that are activated by VEGF-A and inhibit the pathogenic
effects of increased VEGF-A levels [e.g. choroidal neovasculariza-
tion (CNV)], while maintaining the beneficial effects of VEGF-A
(e.g. neuroprotective functions of VEGF-A), and which do not
impair tissue perfusion.
Whether increased VEGF-A levels are merely a consequence of
aging pathologies or instead a direct pathogenic factor in the
progression of aging eye diseases is not known. This distinction has
important clinical implications, as defining a pathogenic role of
increased VEGF-A signaling in specific aging diseases may suggest
novel therapeutic approaches for these diseases that target VEGF-A
pathway hyperactivation or downstream cellular pathomechanisms
that occur as a consequence of increased VEGF-A levels.
With progressive age, increased hypoxia and oxidative damage
occur in many tissues, which are both inducers of VEGF-A expression
in the retinal pigment epithelium (RPE) (Klettner & Roider, 2009;
Byeon et al, 2010). As VEGF-A itself can induce reactive oxygen
species (ROS) in cells (Monaghan-Benson & Burridge, 2009; Marneros,
2013), we hypothesized that increased VEGF-A may further promote
oxidative damage in tissues in a progressive age-dependent manner
and thereby exacerbate the manifestation of aging pathologies.
For example, VEGF-A induces ROS in endothelial cells in a
NADPH oxidase-/rac1-dependent manner that lead to autophospho-
rylation of the VEGF-A receptor Flk1 and downstream activation of
AKT and ERK, resulting in increased endothelial cell migration and
proliferation, and antioxidants inhibited the mitogenic effects of
VEGF-A in endothelial cells (Abid et al, 2000; Colavitti et al, 2002;
Monaghan-Benson & Burridge, 2009). While VEGF-A can increase
ROS, it also induces the expression of the antioxidant enzyme SOD2
by a rac1-regulated NADPH oxidase-dependent mechanism, which
may serve as a compensatory mechanism to reduce overall oxida-
tive stress in cells (Abid et al, 2001).
Importantly, increased ROS generation has been linked to
common age-related eye diseases, including senile cataracts and
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AMD. Environmental risk factors (e.g. cigarette smoking) that
contribute to oxidative stress and hypoxia have also been associated
with these aging eye diseases (Klein et al, 2005).
In the lens, the extent of oxidative stress plays a central role for
the development of senile cataracts (Berthoud & Beyer, 2009). For
example, reduced activity of the antioxidant enzyme SOD1 has been
reported in human senile cataracts (Rajkumar et al, 2013). More-
over, mice deficient in Sod1 have increased superoxide radicals in
their lenses, decreased levels of the antioxidant glutathione, and
develop cataracts earlier and with higher frequency (Olofsson et al,
2009, 2012), while overexpression of SOD1 in the lens prevented
H2O2-induced cataracts (Lin et al, 2005). Notably, ROS have been
reported to further increase VEGF-A expression in lens epithelial
cells (Zhang, 2010; Neelam et al, 2013), but whether increased
VEGF-A promotes cataract formation is unknown.
In the retina, increased oxidative damage has been linked to the
progression of AMD and experimental models have recapitulated
aspects of AMD as a consequence of oxidation-induced pathomecha-
nisms (Hollyfield et al, 2008). Similarly as in lens epithelial cells
and other cell types, oxidative stress can directly induce VEGF-A in
RPE cells, and we have shown that VEGF-A itself can further
promote ROS generation in RPE cells (Klettner & Roider, 2009;
Byeon et al, 2010; Marneros, 2013). While increased oxidative
damage has been associated with aging diseases in the lens and the
retina and leads to increased VEGF-A levels, it remains unknown
whether increased VEGF-A further promotes age-dependent
increases in oxidative damage in these tissues and exacerbates the
manifestation of age-related eye diseases.
Here, we hypothesized that age-dependent increases in hypoxia
and oxidative damage induce the expression of VEGF-A, which itself
further stimulates ROS generation and thereby promotes aging
pathologies in the lens and the retina. As oxidative damage can
induce NLRP3 inflammasome activation that leads to processing and
secretion of the proinflammatory cytokines IL-1b and IL-18, we also
hypothesized that VEGF-A-induced ROS promote aging pathologies
of the eye at least in part through NLRP3 inflammasome-dependent
mechanisms and that targeting NLRP3 inflammasome components
could inhibit aging pathologies that are promoted by increased
VEGF-A while maintaining the beneficial effects of VEGF-A for the
function of the adult microvasculature. Thus, we tested in genetic
mouse models whether a moderate increase in VEGF-A expression
(~two- to threefold, as it occurs in response to hypoxia or oxidative
stress in aged tissues) leads to increased age-related progressive
pathologies in the lens and the retina, and whether genetic targeting
of NLRP3 inflammasome components or of its regulators can
inhibit the manifestation of these common but distinct aging eye
pathologies.
Results
VEGF-A is expressed in the lens and the RPE throughout life and
increased VEGF-A expression correlates with elevation of
markers of oxidative stress
Here, we utilized a mouse model that has ~two- to threefold
increased VEGF-A levels as a consequence of insertion of a lacZ
cassette into the 30-UTR of the VEGF-A gene that regulates its gene
expression (VEGF-Ahyper mice), reflecting VEGF-A increases as they
occur in aging conditions induced by increased hypoxia or oxidative
damage (Miquerol et al, 1999; Funk et al, 2009; Marneros, 2013).
For example, VEGF-A levels in aqueous humor samples from eyes
of patients with neovascular AMD are ~twofold increased
compared to healthy age-matched controls (Funk et al, 2009). This
moderate increase in VEGF-A in the eye is sufficient to promote
AMD, as anti-VEGF-A antibodies inhibit the progression of neovas-
cular AMD in a subset of patients or in experimental laser-induced
CNV (Campa et al, 2008; Group et al, 2011; Martin et al, 2011).
Thus, VEGF-Ahyper mice are a clinically representative animal
model that allows us to assess the effects of a pathophysiologically
relevant increase in VEGF-A for the manifestation of aging eye
diseases, such as AMD.
Notably, mice that are hypomorphic for VEGF-A due to the inser-
tion of a lacZ cassette at a different site within the 30-UTR of the
VEGF-A gene (VEGF-Ahypo mice) did not show the age-dependent
pathologies observed in VEGF-Ahyper mice, revealing that b-galacto-
sidase expression from the VEGF-A locus does not contribute to
these aging pathologies but that they are indeed a consequence of
increased VEGF-A levels in VEGF-Ahyper mice.
As VEGF-Ahyper mice have a NLS-lacZ cassette in the 30-UTR of
the VEGF-A gene, staining for b-galactosidase can be used to detect
cellular VEGF-A expression in these mice (b-galactosidase appears
as nuclear staining). We found VEGF-A expression in the lens,
retina and ciliary body in eyes of young adult VEGF-Ahyper mice,
while no staining for b-galactosidase (and thus VEGF-A) was found
in the corneas of these mice (Fig 1A–F).
We found that the RPE is a major cell type in the posterior eye
to express VEGF-A in the adult, while expression of VEGF-A was
also noticed in cells of the ganglion cell layer and the inner
nuclear layer of the retina (Fig 1B). This expression pattern was
maintained throughout life and strong VEGF-A expression in the
RPE was also found in > 2-year-old mice (Fig 1G). We observed
~twofold elevated protein levels of VEGF-A in the RPE/choroids
of VEGF-Ahyper mice and a lesser increase in VEGF-A in the
retinas of these mice (Marneros, 2013). This increase in VEGF-A
levels was maintained with age and is similar to the reported
~twofold increase in VEGF-A in aqueous humor samples from
eyes of patients with neovascular AMD, making these mice a
particularly disease-relevant model to investigate the role of
increased VEGF-A for the pathogenesis of neovascular AMD (Funk
et al, 2009).
In the lens, strong VEGF-A expression in the young adult was
found in nucleated lens fibers (Fig 1D). Notably, we found in
24-month-old lenses that this VEGF-A expression in nucleated
lens fibers is maintained in the aged lens (Fig 1H). Thus, VEGF-A
is expressed throughout life in the lens, albeit the function of
VEGF-A for the adult lens is not known. VEGF-A mRNA and
protein levels were increased ~two- to threefold in lenses of adult
VEGF-Ahyper mice, and this increase was maintained with progres-
sive age (Fig 2A). Mainly the VEGF-A isoforms VEGF-A120 and
VEGF-A164 and the VEGF-A receptor Flk1 are expressed in the
adult mouse lens, while Flt1 is not expressed in the adult lens
(Fig 2B).
As we hypothesized that increased VEGF-A may induce oxidative
damage with progressive age, we measured lipid peroxidation
byproducts as markers of increased oxidative stress in these mice.
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Figure 1. VEGF-A is strongly expressed in the RPE/retina, the lens, and the ciliary body in the eye, and its expression is maintained with
progressive age.
A–E Staining for b-galactosidase in 3-month-old VEGF-Ahyper (lacZ/wt) mouse eyes. (A) Low-magnification image shows b-gal+ cells (in blue) in the RPE (white arrow),
retina (blue arrow), ciliary body (black arrow), and lens (orange arrow). Images of (B-E) are higher-magnification images of (A). (B) Strong expression of VEGF-A with
b-gal+ cells is observed in the RPE (short white arrow) and the inner nuclear layer (INL) (long white arrow), while less staining is observed in the ganglion cell layer
(black arrow) of the retina. (C) Ciliary body epithelial cells are b-gal+, similarly as in RPE cells (white arrow). (D) VEGF-A is strongly expressed in nucleated lens fibers
in the adult lens (white arrow). (E) No b-gal+ cells are observed in the corneas of adult VEGF-Ahyper (lacZ/wt) mouse eyes. White arrow shows the stroma of the
cornea, and the black arrow shows the corneal epithelium.
F No staining for b-galactosidase is observed in 3-month-old control wild-type littermate eyes.
G RPE cells maintain strong expression of VEGF-A (b-gal+ cells, white arrow) with progressive age. Immunofluorescence for b-gal in the retina of a
24-month-old VEGF-Ahyper mouse is shown. Choroidal macrophages (F4/80+ cells, yellow arrow) show no b-galactosidase expression, while some
immunolabeling for b-galactosidase is detected in retinal cells of the inner nuclear layer (orange arrow) of the retina. RPE: retinal pigment epithelium;
ONL: outer nuclear layer; INL: inner nuclear layer.
H VEGF-A continues to be highly expressed in nucleated lens fibers in the aged lens (shown is a lens of a 24-month-old VEGF-Ahyper mouse; nuclear b-galactosidase
staining (arrow) reflects cellular VEGF-A expression). Cor: lens cortex; Cap: lens capsule. DAPI labels nuclei (blue).
Data information: Scale bars, 200 lm (A and F), 100 lm (B, C and E), 50 lm (D and G), 25 lm (H).
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We found that serum levels of the lipid peroxidation marker
4-hydroxynonenal (4-HNE) were significantly increased in aged
(11-month-old) VEGF-Ahyper mice, but not in young (6-week-old)
VEGF-Ahyper mice, when compared with age- and gender-matched
control littermate mice, suggesting an age-dependent increase in
oxidative stress in these mice as a consequence of increased VEGF-A
levels (Fig 2C).
Higher VEGF-A levels lead to increased oxidative stress markers
and ERK hyperactivation in the aging lens and promote age-
related nuclear cataract formation that can be inhibited by
targeting Nlrp3 or Il1r1
The co-expression of VEGF-A and its receptor Flk1 in the lens
suggests an autocrine/paracrine effect of VEGF-A on lenticular cells.
Consistent with this hypothesis, we observed hyperactivation of the
VEGF-A downstream target ERK in lenses of VEGF-Ahyper mice
(Fig 3A), which has been implicated in cataractogenesis (Gong et al,
2001; Zatechka & Lou, 2002). Importantly, VEGF-Ahyper mice devel-
oped in an age-dependent progressive manner cataracts whose age-
related onset and increase in severity resembled aspects of human
age-related cataracts (Fig 3B–G), which represent the most frequent
form of cataracts and the most common cause of reversible blindness
(Rao et al, 2011; Petrash, 2013).
In lenses of VEGF-Ahyper mice with mature cataracts, we
observed extensive degeneration of lenticular cells with vacuoliza-
tion in the lens cortex (Fig 3D and E). Similar histologic changes
are also observed in human senile cataracts (Shaikh & Janjua,
1997).
Cataract severity was graded according to the extent of morpho-
logical opacification of the lens in vivo. Mild opacification of the
lens that still allowed a proper fundus examination was classified
as grade 1 (and a completely translucent lens without cataracts
was graded as 0), while increased opacification that restricted a
full fundus examination was classified as grade 2. Complete
opacification of the lens with leukocoria (white pupil) and no red
reflex visible from the fundus represented fully matured cataracts
and were classified as grade 3 cataracts.
In 9- to 12-month-old VEGF-Ahyper mice, about 41% of these
mice had formed mature (grade 3) cataracts, while no wild-type
littermate mice in this age group formed mature cataracts (Fig 4A
and Appendix Fig S1). In > 18-month-old VEGF-Ahyper mice, about
59% of these mice had formed mature (grade 3) cataracts with
complete opacification and leukocoria, while only about 12% of
wild-type mice in this age group formed mature cataracts (Fig 4A
and Appendix Fig S1). In contrast, no mature cataracts were found
in young adult VEGF-Ahyper mice (no mature cataract was
observed in 50 VEGF-Ahyper mice that were up to 3 months old)
(Fig 4A and Appendix Fig S1). This progressive age-dependent
increase in cataract frequency and severity in VEGF-Ahyper mice
mirrors the clinical course of senile cataract formation in elderly
patients.
Targeting Nlrp3 delayed cataract formation in aged mice with
normal VEGF-A levels as well as in VEGF-Ahyper mice (Fig 4B and
Appendix Fig S1). Only about 14% of 9- to 12-month-old VEGF-
Ahyper/Nlrp3/ mice formed mature cataracts (grade 3), in contrast
to the about 41% of VEGF-Ahyper mice that formed mature cataracts
in this age group (while no mature cataracts were observed in
9- to 12-month-old wild-type or Nlrp3/ mice) (Fig 4B and
Appendix Fig S1). Similarly, genetic inactivation of Il1r1 inhibited
age-related cataract formation in mice with normal VEGF-A levels
as well as in VEGF-Ahyper mice with increased VEGF-A levels in
the lens (Appendix Fig S1). These findings reveal contributory
pathogenic roles of VEGF-A and NLRP3 inflammasome-mediated
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Figure 2. Increased VEGF-A expression and 4-HNE levels in aged VEGF-Ahyper mice.
A Left graph: VEGF-A protein levels in lenses of VEGF-Ahyper mice are increased ~threefold throughout life (measured at 2 and at 8.5 months of age; n = 7 mice/group,
two independent experiments). Graph shows mean  SEM. *P-value: 0.0228; ***P-value: 0.0003. Right graph: VEGF-A mRNA levels are similarly increased in lenses of
adult VEGF-Ahyper mice (9 months old; n = 7 mice/group, three independent experiments). Graph shows mean  SEM. **P-value: 0.0095.
B VEGF-A isoforms (mainly VEGF-A120 and VEGF-A164) and the VEGF-A receptor Flk1 are expressed in the adult lens. Flt1 expression was not detected in the lens. N = 3
mice/group.
C Increased serum levels of the lipid peroxidation marker 4-HNE (a marker of increased oxidative damage) in aged, but not in young VEGF-Ahyper mice (*P-value: 0.0325;
n = 7 mice/group, two independent experiments). Graph shows mean  SEM.
Source data are available online for this figure.
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IL-1b activation for the manifestation of age-related lens opacifications
VEGF-Ahyper mice.
Consistent with these findings, we found increased IL-1b expres-
sion in aged lenses with VEGF-A-induced cataracts (Fig 4C). Notably,
we have previously observed that increased oxidative stress promotes
the secretion of active IL-1b by lens epithelial cells (Marneros, 2013).
Thus, our findings suggest that VEGF-A-induced oxidative stress
leads to NLRP3 inflammasome-mediated IL-1b activation in the lens
that promotes cataractogenesis. As VEGF-A can induce ROS in cells
through the activation of NADPH oxidase that lead to autophosphory-
lation of Flk1 and downstream activation of ERK (Abid et al, 2000;
Colavitti et al, 2002; Monaghan-Benson & Burridge, 2009), and as
both ERK hyperactivation and oxidative stress are known inducers of
cataracts, we assessed markers of oxidative stress in lenses of VEGF-
Ahyper mice. We found that increased lenticular VEGF-A levels corre-
lated with markers of oxidative stress in lenses of aged VEGF-Ahyper
mice, such as decreased levels of the major antioxidant in the lens,
reduced glutathione (already prior to cataract formation), and overex-
pression of NADPH oxidase gp91phox in lenses of aged VEGF-Ahyper
mice with cataracts (Fig 4D and E). Moreover, we found compen-
satory overexpression of antioxidant enzymes (SOD1, GPx-1, and
catalase) in aged lenses with cataracts in VEGF-Ahyper mice, but not
in young lenses without cataracts (Fig 4F).
Thus, our data suggest a previously unknown pathogenic role of
increased VEGF-A for cataract formation, which may promote
cataractogenesis by increasing oxidative damage and ERK hyperacti-
vation in the lens. VEGF-A-induced oxidative stress may stimulate
NLRP3 inflammasome activation and lead to the secretion of active
IL-1b to promote cataract formation, consistent with our observation
that (i) oxidative stress can induce IL-1b activation in lens epithelial
cells in vitro (Marneros, 2013), that (ii) increased VEGF-A-induced
oxidative damage in lenses with cataracts in VEGF-Ahyper mice is
associated with increased IL-1b expression, and that (iii) genetic
inactivation of either Nlrp3 or Il1r1 inhibits cataract formation in
VEGF-Ahyper mice.
Increased VEGF-A expression specifically in the RPE leads to RPE
barrier breakdown via Flk1 signaling and is sufficient for the
development of neovascular AMD-like pathologies
We observed in eyes of all VEGF-Ahyper mice examined (> 400 mice
were examined in total, between ages 6 weeks to 34 months)
an age-dependent manifestation of AMD-like pathologies with
CNV and progressive RPE/photoreceptor degeneration (Fig 5,
Appendix Figs S2 and S3) (Marneros, 2013; Ablonczy et al, 2014).
With progressive age, sub-RPE basal laminar-like deposits formed
that were associated with the loss of pigment granules in RPE
cells, atrophy of RPE cells, and photoreceptor degeneration
(Appendix Figs S2 and S3). Thus, AMD-like pathologies occur in
100% of VEGF-Ahyper mice, while similar pathologies were not
observed in any wild-type littermate mice. Moreover, CNV lesions
occur with early onset and can be quantitated in VEGF-Ahyper mice
already at 6 weeks of age.
Increased VEGF-A levels in the RPE/retina of VEGF-Ahyper mice
were associated with RPE barrier breakdown, which preceded the
manifestation of neovessel growth from the underlying choroidal
vessels (Marneros, 2013). We observed in detailed histological anal-
yses and choroidal flat mount stainings that the origin of CNV was
the underlying choroidal vasculature and that CNV lesions were
separated by RPE cells from the photoreceptors (Fig 5A–C). Similarly
as in human AMD, we also found basal laminar deposits and autoflu-
orescent sub-RPE deposit in eyes of aged VEGF-Ahyper mice, while
these were not observed to a comparable extent in eyes of age-
matched littermate control mice (Fig 5, Appendix Figs S2 and S3)
(Marneros, 2013). Thus, spontaneous CNV lesions form in
VEGF-Ahyper mice in a progressive age-dependent manner that
morphologically resemble neovascular AMD lesions in patients, in
which neovessels originate from the choroidal vasculature and often
protrude into the space between Bruch’s membrane and the RPE
(Grossniklaus & Green, 1998). These morphological similarities of
CNV lesions in VEGF-Ahyper mice with those in patients with neovas-
cular AMD further demonstrate that these mice serve as a patho-
physiologically relevant animal model for AMD.
While we found the RPE to be a major source of VEGF-A expres-
sion in the posterior eye, VEGF-A was also expressed in other retinal
cells (Fig 1B). Importantly, we observed that activated retinal glia
cells migrated toward the RPE at sites of CNV lesion formation and
that these glia cells strongly expressed VEGF-A (Marneros, 2013).
These findings raise the important question whether increased
VEGF-A expression in the RPE is sufficient to induce RPE barrier
breakdown and subsequent CNV lesion formation, or whether
neovessel growth is a consequence of increased expression of
VEGF-A in other cells of the retina, such as in activated retinal glia cells.
Thus, we tested here whether increased VEGF-A expression
specifically in the RPE (and not in the retina or circulation) is suffi-
cient to induce RPE barrier breakdown and neovascular AMD-like
pathologies, by generating mice that overexpress VEGF-A only in
the RPE postnatally (Vmd2Cre+/WT/ROSA-STOPfl/fl-VEGF-A164
mice). In Vmd2-Cre+/WT mice, Cre recombinase is expressed specif-
ically in the RPE after day 10 postnatally and not in any other retinal
Figure 3. Higher VEGF-A levels in the lens cause ERK pathway hyperactivation and age-dependent progressive nuclear cataracts.
A Increased ERK1/2 phosphorylation is observed in lenses from VEGF-Ahyper mice (KI) with increased VEGF-A levels already prior to cataract formation (11-month-old
mice with no cataracts (0 cataract)), which is maintained in lenses with mature cataracts (lens of a 26-month-old VEGF-Ahyper mouse with +3 cataract).
Quantification of ERK1/2 phosphorylation in 11-month-old lenses (n = 3/group). Graph shows mean  SEM. ***P-value: 0.0005.
B, C Cataracts with opacification of the lens (B, black arrow) and extruded nuclei (C, white arrow) are observed with progressive age in VEGF-Ahyper mice (here a
representative 30-month-old lens with a cataract is shown).
D, E Histology of lens from (B, C) shows extrusion of sclerotic nucleus (white arrows in C and D) and massive degenerative changes in the lens cortex with vacuolization
(black arrows in D and E). Scale bars, 500 lm (D) and 100 lm (E).
F, G Representative histological images of 21-month-old eyes from WT and VEGF-Ahyper mice. The sclerotic nucleus (red arrow in G) was extruded and the lens cortex
and capsule are separated from the nucleus (white arrow in G). The retina in aged VEGF-Ahyper mice is atrophic and shows degenerative changes (yellow arrow in
G), while the retina (*) and lens (**) appear normal in age-matched WT littermate mice. Scale bars, 200 lm. DAPI (blue, nuclei); phalloidin (green).
Source data are available online for this figure.
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cells (Iacovelli et al, 2011). Therefore, in Vmd2Cre+/WT/ROSA-
STOPfl/fl-VEGF-A164 mice, the main isoform of VEGF-A in the RPE
(VEGF-A164) is specifically overexpressed in the RPE after day 10
postnatally, which allows us to determine the effects of increased
VEGF-A expression in the RPE in the adult without affecting retinal
development. Moreover, no Cre-induced abnormalities were
observed in young Cre heterozygous mice of this strain that we used
for these experiments [we found Cre-induced abnormalities in aged
Vmd2-Cre+/WT mice and in mice homozygous for Cre (He et al,
2014)].
Indeed, we observed RPE barrier breakdown and CNV lesions
of similar size as in VEGF-Ahyper mice in Vmd2Cre+/WT/ROSA-
STOPfl/fl-VEGF-A164 mice, confirming that increased VEGF-A
expression specifically in the RPE is sufficient to induce CNV
(Fig 6A–C). As observed in CNV lesions of VEGF-Ahyper mice and in
human neovascular AMD lesions, CNV lesions originated from the
underlying choroidal vessels and were covered by RPE cells also in
Vmd2Cre+/WT/ROSA-STOPfl/fl-VEGF-A164 mice (Fig 6A). These
findings suggest that RPE-derived VEGF-A induces RPE barrier
breakdown and that this is a critical pathogenic step that is required
for CNV lesion formation.
VEGF-A-induced RPE barrier breakdown in vitro is mediated by
signaling through the VEGF-A receptor Flk1 (Ablonczy & Crosson,
2007). Thus, we tested whether inactivation of Flk1 specifically in
the RPE would inhibit VEGF-A-induced RPE barrier breakdown
and subsequent CNV lesion formation in VEGF-Ahyper mice, by
generating Vmd2Cre+/WTFlk1fl/flVEGF-Ahyper mice. In these mice,
staining of choroidal flat mounts reveals nuclear co-localization of
b-gal expression (reflecting increased VEGF-A expression) and Cre
recombinase (reflecting Flk1 inactivation). Thus, these mice have
increased VEGF-A expression in the RPE, while lacking the Flk1
receptor in the same RPE cells. We found that Vmd2Cre+/WT
Flk1fl/flVEGF-Ahyper mice (in which the majority of RPE cells
were Cre+) showed no RPE barrier breakdown and CNV lesions
even at an advanced age (n = 15 mice, up to 8-month-old mice
were examined), when VEGF-Ahyper mice have developed exten-
sive large CNV lesions (Fig 6D and E, and Appendix Fig S4).
Notably, both Vmd2Cre+/WTFlk1fl/fl mice and Vmd2Cre+/WTFlk1fl/fl
VEGF-Ahyper mice had no significant RPE abnormalities on choroidal
flat mounts.
These findings suggest that VEGF-A-induced RPE barrier
breakdown occurs in a Flk1-dependent manner in vivo and is
required for CNV lesion formation. Therefore, targeting Flk1 signaling
in the RPE may prevent the development of neovascular AMD-like
pathologies, thereby providing a novel therapeutic rationale for the
prevention of neovascular AMD. Moreover, these observations
also validate that the AMD-like pathologies that we have observed
in VEGF-Ahyper mice occur indeed due to increased VEGF-A levels
in the RPE (and are not due to other strain-specific effects). Thus,
our data show in two independent genetic mouse models that
increased VEGF-A in the RPE is sufficient to cause CNV lesions that
originate from the underlying choroidal vasculature as observed in
neovascular AMD, thereby providing strong evidence that an
increase in VEGF-A in the RPE is a critical pathogenic contributor
to neovascular AMD.
VEGF-A-induced CNV is promoted by NLRP3 inflammasome-
mediated IL-1b activation
In contrast to acute laser injury models of neovascular AMD (He &
Marneros, 2013), VEGF-Ahyper mice allow us to investigate which
molecular mechanisms do not only contribute to CNV lesion growth
(measuring CNV lesion size), but also contribute to their sponta-
neous age-dependent induction without experimental injury (mea-
suring CNV lesion numbers).
We found increased NLRP3 immunolabeling in the RPE at sites
of CNV lesion formation and increased expression of NLRP3 and
of proangiogenic IL-1b that is activated by the NLRP3 inflamma-
some in the RPE/choroids of VEGF-Ahyper mice, while IL-18
expression was not increased (Fig 7A–C). This is consistent with
our observation that NLRP3 inflammasome activation (with gener-
ation of the active caspase-1 products p10 and p20) occurs in the
eyes of these mice at sites of RPE barrier breakdown (Marneros,
2013).
Oxidative stress as well as sublytic complement C5b-9 attack on
cells can result in IL-1b release through activation of the NLRP3
inflammasome (Laudisi et al, 2013; Triantafilou et al, 2013), and
C5b-9 was shown to be increased in CNV lesions in human eyes
with AMD (Johnson et al, 2000; Mullins et al, 2014). Furthermore,
complement C1q has been shown to be a potent inducer of the
NLRP3 inflammasome and to be increased in eyes with AMD as well
(Doyle et al, 2012). Consistent with these findings, we found NLRP3
inflammasome activation in the RPE of CNV lesions in VEGF-Ahyper
mice and accumulation of complement C1q and C5b-9 in their CNV
lesions, suggesting a role of both in the activation of the NLRP3
inflammasome in CNV lesions of VEGF-Ahyper mice (Fig 7D–F)
Figure 4. Increased lenticular VEGF-A increases markers of oxidative stress in the lens and targeting NLRP3 delays cataract formation.
A Cataracts progress with age in VEGF-Ahyper mice. Cataracts were graded from +1 (mild), +2 (moderate) to +3 (mature cataract with fully opacified lens). While only
a small subset of > 18-month-old WT mice have mature (+3) cataracts, the majority of VEGF-Ahyper mice of this age group have mature cataracts. Percentile (%) of
mice with graded cataracts is indicated in each age group. 0 = no cataract. Absolute mouse numbers of each group are shown in Appendix Fig S1.
B Targeting Nlrp3 inhibits normal age-dependent cataract formation and delays (but does not prevent) VEGF-A-induced cataract formation in VEGF-Ahyper mice.
Percentile (%) of mice with graded cataracts is indicated in each age group. 0 = no cataract. Absolute mouse numbers of each group are shown in Appendix Fig S1.
C Expression of IL-1b in lenses of 21-month-old VEGF-Ahyper mice with +3 cataracts is increased compared to lenses from age-matched WT mice with +3 cataracts,
but not in lenses from 11-month-old mouse groups with no cataracts. *P-value: 0.0259. N = 7/group (three independent experiments).
D VEGF-Ahyper mice have decreased levels of the major antioxidant in the lens, reduced glutathione (in lmol/gm lens weight), prior to cataract formation. Lenses with
0 to +1 cataracts from 11-month-old mice were used for measurements. **P-value: 0.0097. N = 7/group (two independent experiments).
E, F Overexpression of NADPH oxidase gp91phox (*P-value: 0.0435) (E) and of the antioxidant enzymes SOD1 (*P-value: 0.0330), catalase (CAT) (*P-value: 0.0448), and
GPx-1 (*P-value: 0.0443) (F) in 21-month-old lenses of VEGF-Ahyper mice with cataracts (+3), but not in 11-month-old lenses with no cataracts. N = 7/group (three
independent experiments).
Data information: Graphs show mean  SEM.
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Figure 5. Choroidal neovessels originate from the choroidal vasculature in 21-month-old VEGF-Ahyper mice.
A, B Choroidal flat mount staining of a white VEGF-Ahyper mouse shows choroidal vessels [fluorescein-conjugated isolectin B4 (green)] from which neovessels [CD31
(strong red)] originate and that are covered by a RPE cell layer [phalloidin (white)], which separates the CNV lesion from the photoreceptors. White arrows
demarcate CNV lesion. Yellow arrows show round autofluorescent deposits. Scale bars, 100 lm.
C Section through a CNV lesion in a VEGF-Ahyper mouse. Bruch’s membrane location is indicated by yellow arrows. Choroidal neovessels (white arrows) are covered by
a layer of RPE cells (black arrows). Chor: choroid; ONL: outer nuclear layer; PR: photoreceptor outer and inner segments. Scale bar, 20 lm.
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Figure 6. Increased VEGF-A in the RPE causes neovascular AMD-like pathologies by inducing RPE barrier breakdown through activation of Flk1 signaling in
the RPE.
A–C RPE-specific overexpression of VEGF-A in Vmd2Cre+/WTROSA-STOPfl/flVEGF-A164 mice (VEGF-ARPE mice) results in CNV at sites of VEGF-A overexpression [Cre+
patches (white nuclei); red arrow], while Cre areas with normal VEGF-A expression show no CNV (white arrow). Neovessels are CD31+ (red). VEGF-A-induced CNV
lesions and RPE barrier breakdown in Vmd2Cre+/WTROSA-STOPfl/flVEGF-A164 mice resemble those seen in VEGF-Ahyper mice (B and C, arrows; phalloidin staining in
green). Scale bars, 100 lm.
D, E Genetic inactivation of Flk1 specifically in the RPE in VEGF-Ahyper mice (Vmd2Cre+/WTFlk1fl/flVEGF-Ahyper mice) inhibits RPE barrier breakdown and CNV lesion
formation. Choroidal flat mounts of 5-month-old VEGF-Ahyper mice and Vmd2Cre+/WTFlk1fl/flVEGF-Ahyper mice are shown. b-gal staining shows uniform VEGF-A
expression in these mice (green). Cre staining (red) shows co-localization of b-gal and Cre staining in the nuclei of RPE cells in Vmd2Cre+/WTFlk1fl/flVEGF-Ahyper mice
(some red areas of staining occur in CNV lesions of VEGF-Ahyper mice due to labeling of mouse IgG and not Cre, as anti-mouse IgG secondary antibodies were used
to detect the mouse anti-Cre antibody). Phalloidin staining (white) reveals extensive RPE barrier breakdown and CNV lesions (arrow) in VEGF-Ahyper mice, which is
not observed in Vmd2Cre+/WTFlk1fl/flVEGF-Ahyper mice. Scale bar, 100 lm.
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(Marneros, 2013). The observation of key markers that accumulate
in human eyes with AMD also in evolving AMD-like lesions in
eyes of VEGF-Ahyper mice (e.g. the accumulation of complement
C1q and C5b-9) further supports the clinical significance and
pathophysiological relevance of findings in this AMD mouse model
for the human disease.
The NLRP3 inflammasome activates IL-1b and IL-18, and consis-
tent with the increased expression of NLRP3 and IL-1b in the RPE/
choroids of eyes of VEGF-Ahyper mice, we found that the NLRP3
inflammasome promotes VEGF-A-induced CNV lesion formation
through the proangiogenic factor IL-1b, as genetic inactivation of
Nlrp3 or Il1r1 potently reduced the numbers of CNV lesions that
formed in VEGF-Ahyper mice (Fig 8A–E and Appendix Fig S5A
and B). We counted CNV lesions and measured their circumferential
area in choroidal flat mount stainings in 6-week-old mice of each
experimental group. VEGF-Ahyper mice at 6 weeks of age had an
average of 18.41 CNV lesions per eye, while VEGF-Ahyper/Il1r1/
mice (lacking IL-1b signaling activity) had an average of only 8.79
CNV lesions per eye (P-value compared to VEGF-Ahyper mice of
0.0085). VEGF-Ahyper/Nlrp3/ mice (lacking NLRP3 inflammasome
activity that activates IL-1b) had only 6.26 CNV lesions per eye
(P-value compared to VEGF-Ahyper mice of 0.0002). No CNV lesions
were observed in age-matched littermate control mice (obtained
from heterozygous matings between VEGF-Ahyper mice), or in mice
lacking Nlrp3 or Il1r1 (> 30 mice for each of these control groups
were examined).
In our initial observations with a small number of mice, we
had observed that VEGF-Ahyper mice lacking Il18 showed a trend
toward having more CNV lesions, but the observed high variability
within this group of mice and the small sample number resulted
in statistically inconclusive results (Marneros, 2013). Here, we
analyzed CNV lesion numbers and sizes in a large number of age-
matched (6-week-old) mice and could show that targeting Nlrp3 or
Il1r1 significantly reduced CNV lesion numbers (but not CNV
lesion sizes), while targeting Il18 did not show a statistically signif-
icant change in either CNV lesion numbers or their size (Fig 8A
and B, and Appendix Fig S5A and B). Thus, VEGF-A-induced CNV
lesion induction in this mouse model of AMD is promoted by
NLRP3 inflammasome-mediated generation of the highly proangio-
genic factor IL-1b (but not by IL-18). These findings in the
posterior eye resemble our observations in the lenses of aged
VEGF-Ahyper mice and demonstrate that both VEGF-A-induced age-
related cataract formation and CNV are strongly promoted by
NLRP3 inflammasome-mediated IL-1b activation, suggesting a
shared VEGF-A-induced pathomechanism for these distinct aging eye
pathologies.
Targeting caspase-1/caspase-11 potently inhibits CNV lesion
formation and growth
Caspase-1 activation is essential for inflammasome-mediated gener-
ation of active IL-1b and IL-18, while the proinflammatory caspase-
11 has a critical role in activating caspase-1 and has also been
shown to lead to pyroptotic cell death in a caspase-1-independent
manner (Kayagaki et al, 2011). Moreover, caspase-11 promotes cell
migration during inflammation and lack of caspase-11 inhibits
macrophage migration (Li et al, 2007). We and others have
observed that infiltrating macrophages promote laser-induced CNV
formation (Espinosa-Heidmann et al, 2003; Sakurai et al, 2003;
Caicedo et al, 2005; Semkova et al, 2011; Shi et al, 2011; He &
Marneros, 2013; Marneros, 2013). Thus, we hypothesized that the
lack of both inflammatory caspases (caspase-1 and caspase-11) may
inhibit CNV formation more potently than targeting Nlrp3 or IL-1b
signaling alone. Indeed, we observed that genetic inactivation of
caspase-1/caspase-11 in VEGF-Ahyper mice strongly inhibited both
CNV lesion formation and growth, while targeting Nlrp3 or Il1r1
inhibited CNV lesion formation less potently and had no effect on
CNV lesion growth (Fig 8A–E and Appendix Fig S5A and B).
Average CNV lesions per eye were for 6-week-old VEGF-Ahyper mice
18.41, for VEGF-Ahyper/Il1r1/ mice 8.79, for VEGF-Ahyper/Nlrp3/
mice 6.26, but for VEGF-Ahyper/Casp1//Casp11/ mice only
2.71 (P-value compared to VEGF-Ahyper mice of 0.0002). Average
CNV lesion size in 6-week-old VEGF-Ahyper mice was 22,265 lm2,
while CNV lesions in VEGF-Ahyper/Casp1//Casp11/ mice
were on average only 10,137 lm2 in size (P-value compared to
VEGF-Ahyper mice of < 0.0001). These findings reveal caspase-1/
caspase-11 as potential novel promising therapeutic targets in
neovascular AMD.
CNV lesion size is regulated by autophagy and TLR2 signaling
The NLRP3 inflammasome can be activated by oxidative stress and
TLR signaling and inhibited by autophagy in vitro (Netea et al,
2009; Into et al, 2010; Miura et al, 2013). Notably, we have
observed increased expression of TLR2 in RPE cells of VEGF-Ahyper
mice and strong labeling for TLR2 in CNV lesions of these mice
(Fig 7G) (Marneros, 2013). Moreover, TLR2 has been shown to
promote angiogenesis in response to oxidative stress (West et al,
2010).
As we have shown that VEGF-A can induce oxidative stress in
the RPE in vitro and as the RPE in VEGF-Ahyper mice shows evidence
of increased oxidative damage as well (Marneros, 2013), we hypoth-
esized that increased oxidative stress-induced TLR2 signaling may
promote NLRP3 inflammasome-mediated CNV lesions in VEGF-
Ahyper mice, while autophagy (having a potential inhibitory effect on
the NLRP3 inflammasome) may reduce CNV. Consistent with this
hypothesis, we found a strongly reduced CNV lesion size in VEGF-
Ahyper/Tlr2/ mice and a moderate increase in CNV lesion size in
VEGF-Ahyper mice with reduced autophagy (due to heterozygosity
for the critical autophagy gene beclin-1) (Fig 8A and B and
Appendix Fig S5A and B). While the average CNV lesion size in
6-week-old VEGF-Ahyper mice was 22,265 lm2, CNV lesions in
6-week-old VEGF-Ahyper/Tlr2/ mice were on average only
11,742 lm2 in size (P-value compared to VEGF-Ahyper mice of
< 0.0001). Notably, CNV lesion numbers were not affected by defi-
ciency for Tlr2. These findings suggest that increased VEGF-A
induces oxidative stress and a complement-mediated inflammatory
reaction that lead to the activation of the NLRP3 inflammasome,
which promotes CNV lesion induction through the generation of
active IL-1b, while CNV lesion growth is regulated in part by TLR2
signaling and autophagy. Moreover, our findings show that
increased VEGF-A plays a direct pathogenic role in the development
of AMD-like pathologies, supporting the observations in human
AMD.
Notably, adult Nlrp3/, Casp1//Casp11/, Il1r1/, Il18/,
Tlr2/, Becn1/+, or Atg16l1hypo mice showed no obvious
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abnormalities of the choroidal vasculature and developed no
spontaneous CNV lesions (> 30 age-matched mice per group were
examined).
As we have observed that genetic inactivation of caspase-1/
caspase-11 or Tlr2 results in reduced CNV growth in VEGF-Ahyper
mice, we next tested whether we can obtain further support for
these findings in a non-genetic independent experimental mouse
model of CNV and whether pharmacologic inhibition of these
pathways may provide a therapeutic approach to inhibit CNV
growth. Thus, we tested the effects of treatment of wild-type
mice either with a small-molecule inhibitor of caspase-1 or with
neutralizing anti-TLR2 antibodies in laser injury-induced CNV
experiments. Laser injury to the RPE/choroid induces CNV lesion
formation in this model that can be readily quantified 7 days after
experimental injury (He & Marneros, 2013). Consistent with the
observed reduced CNV lesion growth in VEGF-Ahyper/Casp1//
Casp11/ mice compared to VEGF-Ahyper mice, we observed that
pharmacologic inhibition of caspase-1 significantly reduced laser-
induced CNV lesion growth when compared to DMSO-treated control
mice (Fig 8F). Furthermore, treatment with neutralizing TLR2 anti-
bodies also significantly reduced laser-induced CNV lesion growth,
similarly as observed when targeting Tlr2 genetically in VEGF-Ahyper
mice (Fig 8F).
Progressive VEGF-A-induced RPE and photoreceptor
degeneration and decline in visual function are mediated in part
by NLRP3 inflammasome-dependent IL-1b activation and can be
inhibited by targeting Nlrp3, caspase-1/caspase-11, or Il1r1
VEGF-Ahyper mice develop progressive basal laminar sub-RPE
deposits and degeneration of the RPE and photoreceptors,
resembling aspects of non-exudative AMD (Fig 9B and
Appendix Figs S2 and S3). Initial degenerative changes are observed
already in young VEGF-Ahyper mice, but these changes progress with
increasing age and are particularly prominent in mice > 12 months
of age. In addition, autofluorescent sub-RPE deposits are observed
in aged VEGF-Ahyper mice (Figs 5A and B, and 11B). These age-
dependent eye pathologies occurred also at sites devoid of CNV
lesion formation (making it unlikely that they are a consequence of
CNV) and were not observed in age- and gender-matched wild-type
littermate control mice or in VEGF-Ahypo mice, which are hypomor-
phic for VEGF-A and express b-galactosidase from the endogenous
VEGF-A locus (thereby excluding a contributory role of b-galactosi-
dase expression for these pathologies) (Fig 9A and I). Similarly as in
human AMD, the age-dependent AMD-like pathologies in VEGF-
Ahyper mice were associated with progressive attenuation of visual
function with diminished electroretinogram (ERG) amplitudes
and reduced rhodopsin levels, providing further evidence for the
clinicopathologic relevance of these morphologic observations for
human AMD (Ablonczy et al, 2014).
In preliminary experiments with 6-week- to 2-month-old VEGF-
Ahyper mice that lacked either Nlrp3, Il1r1, or Il18, we had previ-
ously observed the occasional occurrence of some VEGF-A-induced
chorioretinal pathologies, but we had not performed a detailed anal-
ysis of the age-dependent AMD-like pathologies in these mice with
progressive age (Marneros, 2013). Thus, we investigated here
whether inactivation of inflammasome components can inhibit not
only VEGF-A-induced CNV, but also degenerative changes of the
RPE and photoreceptors in aged VEGF-Ahyper mice.
Indeed, genetic inactivation of Casp1/Casp11, Nlrp3, or Il1r1
inhibited the manifestation of age-dependent RPE and photoreceptor
degeneration in aged VEGF-Ahyper mice, while this effect was not
observed in VEGF-Ahyper mice that lacked Il18 or that were
heterozygous for the key autophagy gene beclin-1 (Fig 9B–H).
For example, 21-month-old VEGF-Ahyper mice showed severe degen-
erative and atrophic changes of the RPE, thick basal laminar
sub-RPE deposits, shortening of photoreceptor outer and inner
segments, and attenuation of the photoreceptor outer nuclear layer
(ONL) (Fig 9B and Appendix Figs S2 and S3). In contrast, these
pathologies were much reduced in VEGF-Ahyper mice that lacked
Nlrp3, Casp1/Casp11, or Il1r1 (Fig 9C–E).
Notably, RPE and photoreceptor degeneration was still present
in aged VEGF-Ahyper/Il18/ mice, which formed thick sub-RPE
deposits that protruded into the RPE plane (Fig 9F and G).
In order to obtain a clinicopathological correlation of these
morphological abnormalities of the RPE and photoreceptors, and
to demonstrate that the visual function decline in aged VEGF-
Ahyper mice can be rescued by targeting NLRP3 inflammasome
components, we performed dark-adapted (to assess mainly rod
function) and light-adapted (to assess mainly cone function) elec-
troretinograms (ERGs) in 21-month-old mice of these experimental
groups. While in 21-month-old VEGF-Ahyper mice ERG amplitudes
(a- and b-waves) for both dark-adapted and light-adapted condi-
tions were severely diminished (consistent with the severe RPE
and photoreceptor degeneration observed by histologic analysis),
targeting caspase-1/caspase-11 or Il1r1 in VEGF-Ahyper mice
partially normalized ERG amplitudes (Fig 10A–C).
The improvement of visual function in aged VEGF-Ahyper mice by
blocking inflammasome activation is consistent with the inhibition
of morphological degenerative changes observed in these mice. The
presence of RPE and photoreceptor degeneration in VEGF-Ahyper/
Il18/ mice is also supported by the observation that targeting
Il18 did overall not improve ERG amplitudes and visual function in
aged VEGF-Ahyper mice (Fig 10A–C).
Figure 7. Increased NLRP3, complement C1q and C5b-9 in CNV lesions of VEGF-Ahyper mice.
A NLRP3 is expressed in RPE cells at sites of CNV lesions (arrow; white). Scale bar, 100 lm.
B Lack of NLRP3 staining in VEGF-Ahyper/Nlrp3/ mice (control). Scale bar, 100 lm.
C Expression of NLRP3 (*P-value: 0.0478) and IL-1b (*P-value: 0.0398), but not of IL-18 (P-value: 0.3529), is increased in RPE/choroid lysates from VEGF-Ahyper mice
when compared to matched control littermate mice. N = 7 mice/group (three independent experiments). Graphs show mean  SEM.
D–G Complement pathway activation (immunolabeling for the product of complement pathway activation C5b-9, an inducer of the NLRP3 inflammasome) is
observed in CNV lesions of VEGF-Ahyper mice (white arrow in E), but not in age-matched control mice (D). Co-localization of C5b-9 in the same CNV
lesion is observed with complement C1qA (the initiator of the classical complement pathway and an inducer of the NLRP3 inflammasome) (F) and with
TLR2 (G) (white arrows). Autofluorescence (auto) in red in (D) and (E). CD31+ vessels in red in (F) and (G). Yellow arrows show site of choroid. Scale bars,
50 lm.
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To further strengthen the clinicopathologic correlation of these
findings, we assessed additional clinical parameters observed in
AMD in those aged mice in which we performed ERGs by fundus
imaging, autofluorescence analysis of the fundus, and optical coher-
ence tomography (OCT).
OCTs in aged VEGF-Ahyper mice showed severe degenerative
changes in the retina and CNV lesions originating from the choroid,
which were much reduced in age-matched VEGF-Ahyper/Casp1//
Casp11/ mice and not seen in Casp1//Casp11/ mice
(Fig 11A).
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Autofluorescence imaging of the fundus showed areas of strong
autofluorescence in fundus images of aged VEGF-Ahyper mice, a
feature associated with autofluorescent sub-RPE deposits as
observed in AMD (Fig 11B). Notably, VEGF-Ahyper/Casp1//
Casp11/ mice and Casp1//Casp11/ mice showed much fewer
or no autofluorescent deposits.
Consistent with the morphological and functional findings of RPE
and photoreceptor degeneration in aged VEGF-Ahyper mice, we also
found abnormal pigmentation of the fundus in these mice, while
VEGF-Ahyper/Casp1//Casp11/ mice had a largely normal
appearing fundus compared to the Casp1//Casp11/ mice
(Fig 11C). Thus, the inhibition of the observed AMD-like pathologies
in VEGF-Ahyper mice by targeting caspase-1/caspase-11 is supported
by the functional assessment of visual function (ERGs) and by
clinical imaging techniques (OCTs and fundus imaging) in
these mice. In conclusion, NLRP3 inflammasome-mediated IL-1b
activation promotes VEGF-A-induced progressive eye pathologies
that resemble aspects of both neovascular AMD (CNV) and non-
exudative AMD (RPE/photoreceptor degeneration and accumulation
of sub-RPE deposits).
Discussion
Our findings suggest a direct pathogenic role of increased VEGF-A
for the manifestation of age-related lens opacifications and for
both neovascular and non-exudative AMD-like pathologies through
NLRP3 inflammasome-dependent mechanisms. Thus, VEGF-A-
induced pathways and NLRP3 inflammasome components may
serve as novel therapeutic targets to inhibit these major common
aging diseases of the eye without impairing the adult micro-
vasculature, as would be expected to occur when targeting VEGF-A
continuously.
Importantly, increased VEGF-A levels accelerated age-related
changes that normally occur in these tissues and promoted the tran-
sition of these normally occurring aging changes to pathologic organ
dysfunction. For example, the progressive opacification in the lens
that occurs with increasing age in wild-type mice was increased and
exacerbated in VEGF-Ahyper mice that have increased VEGF-A levels
in their lenses, leading to more frequent and earlier-onset cataracts
when compared to age-matched control mice.
Thus, reducing increased VEGF-A activity in aging tissues may
inhibit both normal aging-associated functional declines in these
tissues and the manifestation of age-related diseases. For example,
reducing environmental factors or other changes that promote
increased hypoxia or oxidative stress may lead to normalization of
VEGF-A levels in aging tissues and inhibit the progression of these
aging-associated pathologies.
This hypothesis is consistent with clinical studies suggesting that
a diet high in antioxidants may slow the progression of advanced
AMD and of age-related cataracts (Chew et al, 2013; Rautiainen
et al, 2014).
However, an increase in VEGF-A may also have beneficial effects
in some aging tissues, where induced VEGF-A expression may be
critical to stimulate compensatory angiogenesis and improve tissue
perfusion in response to tissue hypoxia. Thus, targeting VEGF-A
directly may have detrimental effects in these conditions.
This is consistent with observed adverse effects of anti-VEGF-A
therapies, likely as a consequence of abolishing important roles of
VEGF-A for the maintenance and regulation of the adult microvascu-
lature (Kamba et al, 2006). These effects of anti-VEGF-A therapies
have been reported to precipitate clinical adverse reactions in some
patients, including hypertension, increased risk of hemorrhage or
thromboembolic events, or cardiac ischemia (Kamba & McDonald,
2007). Thus, it is highly desirable to identify novel therapeutic
approaches that inhibit the pathogenic effects of increased VEGF-A
levels for the manifestation of aging diseases without causing the
side effects that occur when neutralizing VEGF-A directly. Our find-
ings suggest that inhibition of NLRP3 inflammasome components
could serve as such a comprehensive novel therapeutic approach
that can inhibit the downstream effects of VEGF-A that promote
age-related pathologies, without causing the adverse side effects of
anti-VEGF-A therapies and without impairing tissue vascularization.
Our data reveal a previously unknown role of increased VEGF-A
levels for the induction of oxidative stress in aged lenses that is
associated with the development of age-related lens opacifications,
and we show that targeting Nlrp3 or Il1r1 inhibits VEGF-A-induced
age-related cataractogenesis.
Figure 8. VEGF-A-induced AMD-like pathologies occur in an NLRP3 inflammasome- and IL-1b-mediated process, which is regulated by TLR2 signaling and
autophagy pathways.
A CNV lesion numbers per eye in 6-week-old VEGF-Ahyper mice compared with VEGF-Ahyper mice lacking Casp1/Casp11, Nlrp3, Il1r1, Il18, Tlr2, or those
heterozygous for beclin-1 or homozygous for hypomorphic Atg16l1. Casp1/Casp11, Nlrp3, or Il1r1 deficiency results in significantly fewer CNV lesions. Each
value represents the total CNV lesion number/eye for an individual mouse. Mean  SEM is shown. P-values are based on comparison with the VEGF-Ahyper
mouse group. Absolute numbers of mice per group are indicated in parentheses. P-values were calculated with a two-tailed unpaired Student’s t-test.
Separately, P-values are shown between VEGF-Ahyper/Casp1//Casp11/ and VEGF-Ahyper/Nlrp3/ or VEGF-Ahyper/Il1r1/ mouse groups. WT mice
developed no CNV lesions.
B Average CNV lesion area (in lm2/lesion) in 6-week-old VEGF-Ahyper mice compared with VEGF-Ahyper mice lacking Casp1/Casp11, Nlrp3, Il1r1, Il18, Tlr2, or those
heterozygous for beclin-1 or homozygous for hypomorphic Atg16l1. Lack of Tlr2 or Casp1/Casp11 significantly reduces CNV lesion size, while reduced autophagy
moderately increases CNV size. Each value represents the average CNV lesion size/eye for an individual mouse. Mean  SEM is shown. P-values are based on
comparison with the VEGF-Ahyper mouse group. Absolute numbers of mice per group are indicated in parentheses. P-values were calculated with a two-tailed
unpaired Student’s t-test. Separately, P-values are shown between VEGF-Ahyper/Casp1//Casp11/ and VEGF-Ahyper/Nlrp3/ or VEGF-Ahyper/Il1r1/ mouse
groups.
C–E Representative choroidal flat mount images show multifocal CNV lesions in VEGF-Ahyper mice and a significant reduction in CNV numbers in those VEGF-Ahyper
mice that lack either Casp1/Casp11 or Il1r1 (and therefore IL-1b signaling). Staining for phalloidin in green and for CD31 in red. Scale bars, 200 lm.
F Laser-induced CNV experiments demonstrate that treatment with a caspase-1 inhibitor (compared to DMSO-treated controls) or a neutralizing TLR2 antibody
(compared to isotype-matched IgG-treated controls) inhibits CNV lesion growth. P-values are shown. Mean  SEM is shown. N = 15 mice/group. Representative
CNV lesions in choroidal flat mounts are shown. Scale bars, 100 lm.
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Similarly, we demonstrate here that VEGF-A-induced CNV and
degeneration of the RPE and photoreceptors can be potently inhib-
ited by genetically inactivating NLRP3 inflammasome components
or Il1r1 in VEGF-Ahyper mice. Thus, pharmacologic inhibition of
the NLRP3 inflammasome or of IL-1b signaling may inhibit both
AMD and senile cataract progression. For example, we show here
that a caspase-1 inhibitor potently inhibited laser-induced CNV
growth (Fig 8F). Similarly, a specific small chemical inhibitor of the
NLRP3 inflammasome has been reported that may thus be used
therapeutically to inhibit these aging diseases (Coll et al, 2015).
Alternatively, IL-1b blockers could also have clinical benefit in the
prevention or inhibition of AMD or age-related cataract formation
(Dhimolea, 2011).
Strikingly, combined inhibition of the inflammatory caspases,
caspase-1 and caspase-11, reduced not only the number of CNV
lesions that formed in VEGF-Ahyper mice (as observed when
VEGF-Ahyper/Il1r1-/-VEGF-AhyperB C
VEGF-Ahyper/Casp1-/-/Casp11-/-D VEGF-Ahyper/Nlrp3-/-E
VEGF-Ahyper/Becn1+/-H VEGF-AhypoI
VEGF-Ahyper/Il18-/-
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Figure 9. VEGF-A-induced degeneration of the RPE and photoreceptors can be inhibited by targeting Nlrp3, Il1r1, or caspase-1/caspase-11 in VEGF-Ahyper
mice.
A No significant abnormalities of the choroid, RPE, or retina are seen in control wild-type littermate mice. Representative image of a 28-month-old control eye is
shown. White arrow indicates normal Bruch’s membrane. Chor: choroid; RPE: retinal pigment epithelium; PR: photoreceptor outer and inner segments; ONL: outer
nuclear layer.
B Aged VEGF-Ahyper mice develop a progressive age-dependent degeneration of the RPE (red arrow) and the photoreceptors (yellow arrow) with accumulation of thick
sub-RPE basal laminar deposits (black arrow). These pathologies occur also at sites devoid of CNV lesions.
C–E Genetic inactivation of Casp1/Casp11, Nlrp3, or Il1r1 strongly inhibits the manifestation of RPE and photoreceptor degeneration in aged VEGF-Ahyper mice.
F, G VEGF-Ahyper/Il18/ mice show a significant RPE and photoreceptor degeneration, with shortened and irregular photoreceptor outer segments (white arrows). Thick
sub-RPE deposits that protrude into the RPE plane are observed as well (black arrows).
H VEGF-Ahyper/Becn1+/ mice show RPE and photoreceptor degeneration.
I In contrast, age-matched VEGF-Ahypo mice that are hypomorphic for VEGF-A and express b-galactosidase from the endogenous VEGF-A locus do not show these eye
pathologies.
Data information: Representative images in (B–I) are from eyes of 21-months old mice. Scale bars, 20 lm.
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targeting Nlrp3), but also the size of CNV lesions. Moreover, target-
ing these caspases inhibited VEGF-A-induced degeneration of the
RPE and photoreceptors and the age-dependent decline in visual
function. Thus, our findings suggest that inflammatory caspases
could be important novel therapeutic targets in the comprehensive
treatment or prevention of both neovascular and non-exudative
AMD, and indicate that targeting inflammatory caspases may inhibit
AMD more potently than when targeting Nlrp3 or IL-1b signaling.
Figure 10. Targeting caspase-1/caspase-11 or Il1r1 partially rescues the loss of visual function in aged VEGF-Ahyper mice.
A Graphs show means of a- and b-waves of dark-adapted and light-adapted ERG responses (ERG intensities in lV) for both the left and the right eyes from 21-month-
old VEGF-Ahyper mice, VEGF-Ahyper/Casp1//Casp11/ mice, Casp1//Casp11/ mice, VEGF-Ahyper/Il1r1/ mice, Il1r1/ mice, VEGF-Ahyper/Il18/ mice, and Il18/
mice. None of these mice had cataracts. Graphs show mean  SEM. P-values are indicated in (C).
B Representative ERG tracings are shown for VEGF-Ahyper mice and for VEGF-Ahyper/Casp1//Casp11/ mice. X-axes show milliseconds (ms). Y-axes show ERG
intensities (in lV).
C For each experimental mouse group, means for a- and b-waves of ERGs were calculated and P-values are shown for left and right eyes using a two-tailed unpaired
Student’s t-test. P-values of the VEGF-Ahyper mouse group are compared to those VEGF-Ahyper mice lacking either Casp1/Casp11, Il1r1, or Il18, as well as to the KO
mice (Casp1//Casp11/ mice, Il1r1/ mice, or Il18/ mice) without the VEGF-Ahyper allele. In addition, P-values are shown comparing values between the KO
mouse groups and those that have the VEGF-Ahyper allele. Mouse numbers for each experimental mouse group are indicated as well.
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Figure 11. Lack of caspase-1/caspase-11 inhibits CNV lesion formation, retinal degeneration, fundus abnormalities, and fundus autofluorescence in aged
VEGF-Ahyper mice.
Representative images of 21-month-old mice are shown.
A OCTs in aged VEGF-Ahyper mice show retinal degeneration with a thinning of the retina and CNV lesions originating from the choroid (arrows). OCTs do not show the
same degree of abnormalities in age-matched VEGF-Ahyper/Casp1//Casp11/ mice and Casp1//Casp11/ mice.
B Fundus autofluorescence imaging shows areas of autofluorescence in the fundus of aged VEGF-Ahyper mice (arrow), but not in age-matched VEGF-Ahyper/Casp1//
Casp11/ mice and Casp1//Casp11/ mice.
C Abnormal pigment loss and degenerative changes are observed in the fundi of aged VEGF-Ahyper mice (arrow), while the fundi of age-matched VEGF-Ahyper/Casp1//
Casp11/ mice and Casp1//Casp11/ mice do not show these abnormalities.
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Furthermore, we identified inflammasome-independent thera-
peutic targets for neovascular AMD by showing that targeting
VEGF-A/Flk1 signaling in the RPE prevents RPE barrier breakdown
and CNV, while the inhibition of TLR2 may inhibit the growth of
these CNV lesions.
In summary, our data demonstrate that increased VEGF-A levels,
as they can occur in aging tissues due to increased hypoxia or
oxidative damage, exacerbate normal age-associated changes and
may lead to the manifestation of progressive pathologies resembling
those in human senile cataracts and AMD, suggesting shared path-
omechanisms between these distinct age-related eye diseases. The
manifestation of these common VEGF-A-induced aging eye patholo-
gies can be strongly inhibited by targeting components of the
NLRP3 inflammasome. Thus, targeting NLRP3 inflammasome
components may serve as a comprehensive unifying therapeutic
approach to simultaneously inhibit or prevent multiple common
aging diseases of the eye, while preserving the beneficial effects of
VEGF-A function.
Materials and Methods
Animals
For all animal studies, institutional approval by Massachusetts
General Hospital was granted. Experiments were performed in
compliance with ARRIVAL guidelines. The generation of VEGF-
Ahyper mice was previously reported (kindly provided by Dr. Andras
Nagy) (Miquerol et al, 1999). Mice between ages 6 weeks to
34 months were examined, in total > 400 mutant and control litter-
mate mice. The increase in VEGF-A levels occurs in these mice as a
consequence of the heterozygous insertion of an IRES-NLS-lacZ-
SV40pA sequence +202 bp 30 to the STOP codon into the 30-UTR of
the VEGF-A gene locus. Nuclear b-galactosidase expression reflects
VEGF-A expression at single-cell resolution in these mice. The
described AMD-like pathologies were observed only in VEGF-Ahyper
mice, while none of the control littermate mice displayed these
RPE/retinal pathologies. We quantified CNV lesions in mice at
6 weeks of age and every single VEGF-Ahyper mouse of > 400
examined mice showed RPE barrier breakdown and CNV lesions.
Thus, the fully penetrant AMD-like phenotypes in VEGF-Ahyper
mice allow for precise comparative quantifications of these eye
pathologies. Furthermore, VEGF-Ahyper mice (VEGF-AlacZ/WT mice)
were obtained through intercrosses with their control littermates
(VEGF-AWT/WT mice) for > 25 generations. The observed ocular
abnormalities always co-segregated with the VEGF-Ahyper allele
(VEGF-AlacZ/WT) and were not observed in any of the examined
control littermate VEGF-AWT/WT mice, making it highly unlikely
that another mutation may have contributed to the observed
ocular abnormalities in VEGF-Ahyper mice. By utilizing littermate
mice (VEGF-AWT/WT mice from VEGF-AlacZ/WT intercrosses) as
controls for the VEGF-Ahyper mice, we ensured the same genetic
background.
Mice in which the IRES-NLS-lacZ-SV40pA sequence was inserted
immediately 30 to the STOP codon into the 30-UTR of the VEGF-A
gene locus are hypomorphic for VEGF-A (VEGF-Ahypo mice),
but maintain b-galactosidase expression from the endogenous
VEGF-A gene locus (Damert et al, 2002). While these mice showed
b-galactosidase expression in the same cells and tissues as seen in
VEGF-Ahyper mice, the pathologies in VEGF-Ahyper mice were not
observed in these VEGF-Ahypo mice, demonstrating that these
pathologies are not caused by insertion of the lacZ sequence and
expression of b-galactosidase (Fig 9I). VEGF-Ahyper mice were crossed
with Il18/, Il1r1/, Casp1//Casp11/, Nlrp3A350VneoR mice,
Tlr2/, beclin-1/WT, and Atg16l1hypo mice (mice from JAX were
on a C57BL/6 genetic background; Atg16l1hypo mice were kindly
provided by Dr. Skip Virgin) (Glaccum et al, 1997; Takeda et al,
1998; Brydges et al, 2009). Homozygous Nlrp3A350VneoR-knockin
mice contain a floxed neoR cassette in opposite orientation in
intron 2 of the Nlrp3 gene leading to the lack of functional Nlrp3
gene expression in the absence of Cre expression (here referred to
as Nlrp3/ mice) (Brydges et al, 2009). We confirmed the absence
of an Nlrp3 transcript by RT–PCR with primers spanning exons 2
and 3 (exon 3 contains the NACHT domain, which is critical for
the role of NLRP3 in inflammasome activation) (Appendix Fig S6).
Mice deficient in caspase-1 have also an incidental caspase-11
deficiency, the murine homolog of CASP4 (referred to as Casp1//
Casp11/ mice), and caspase-11 has been shown to be involved
in caspase-1 activation (Li et al, 1995; Wang et al, 1998; Kayagaki
et al, 2011). None of these null mice (without the VEGF-Ahyper
allele) developed CNV lesions (> 30 mice/group were examined).
To generate mice with RPE-specific overexpression of VEGF-A, we
crossed Vmd2-Cre mice that express Cre recombinase driven by
the RPE-specific promoter Vmd2 after P10 (from JAX) with ROSA-
STOPfl/fl-VEGF-A164 mice (kindly provided by Dr. Andras Nagy) to
generate mice that specifically overexpress VEGF-A164 in the
RPE postnatally (Vmd2-Cre+/WT/ROSA-STOPfl/fl-VEGF-A164 mice)
(Iacovelli et al, 2011). RPE-specific Cre expression was confirmed
by immunolabeling for Cre. In addition, we crossed Flk1fl/fl mice
(from JAX) with Vmd2-Cre+/WT mice and VEGF-Ahyper mice to
generate Vmd2-Cre+/WTFlk1fl/flVEGF-Ahyper mice. Both the rd1 and
the rd8 mutations were excluded in all mouse strains analyzed in
this study by PCR. All mutant strains were bred for > 10
generations. All mice were housed under conventional breeding
conditions.
Morphological examination of eyes
For semithin sections, eyes were fixed in 1.25% paraformaldehyde
and 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.4).
After postfixation in 4% osmium tetroxide, and dehydration
steps, tissues were embedded in TAAB epon (Marivac Ltd.), and
1-lm-thin sections were used for toluidine blue staining and light
microscopy. Posterior eye sections were assessed at the level of
the optic nerve, and representative retinal images were obtained
from areas adjacent to the optic nerve in a paracentral location.
Images from similar locations were obtained from each eye,
which allowed a direct comparison of eyes between different
mouse strains. Lens sections were analyzed in both plastic-
embedded semithin sections, as well as in OCT-embedded frozen
sections.
Immunolabeling
Whole eyes were fixed in 4% paraformaldehyde overnight at 4°C
and then washed in PBS. Thereafter, the eyes were dissected along
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the ora serrata. For choroidal flat mounts, eyes were permeabilized
in 0.5% Triton X-100 and blocked with 5% serum in which the
secondary antibodies were raised for 1 h. For frozen sections, fixed
tissues were treated with 30% sucrose and subsequently embed-
ded in OCT and cut at 7 lm thickness (lenses were cut at 2 lm
thickness). Tissue permeabilization was performed with 0.5%
Triton X-100, and blocking was performed with blocking serum in
which the secondary antibody was raised. Incubation with primary
antibodies in blocking solution was performed overnight at 4°C
and then washed in PBS. Primary antibodies used were as follows
(at a 1:50 dilution): rat anti-mouse CD31 (MEC13.3, BD PharMin-
gen), rabbit anti-mouse b-galactosidase (A11132, Life Technolo-
gies), Alexa-647-conjugated rat anti-mouse F4/80 (clone BM8,
Biolegend), mouse anti-Cre (clone 2D8, Millipore), rabbit anti-
NLRP3 (H66, Santa Cruz Biotechnology), rabbit anti-mouse C1qA
(M-120, Santa Cruz Biotechnology), rabbit anti-mouse TLR2
(ab24192, Abcam), and rabbit anti-mouse C5b-9 (ab55811, Abcam).
Fluorescein-conjugated isolectin B4 (Vector) was used for intracar-
diac perfusions to label perfused vasculature. Cytoskeletal staining
was performed with Alexa-488-conjugated phalloidin (Life Technolo-
gies). Co-labeling experiments were combined with single-labeling
experiments and experiments omitting both either the primary or
the secondary antibodies to distinguish immunolabeling from
autofluorescence. Secondary antibodies (at a 1:100 dilution) were
conjugated Alexa-488, Alexa-555, or Alexa-647 antibodies (Life
Technologies) and were incubated for 3 h at room temperature in
the dark. DAPI was used for staining of nuclei (Life Technologies).
Quantification of the size and number of CNV lesions
We used for all CNV quantifications 6-week old mice. The eyes
were enucleated and fixed in 4% paraformaldehyde overnight at
4°C and then washed in PBS. The anterior segment, the lens and
the retina were removed, and the RPE/choroid tissue (posterior
eye) was treated with 0.5% Triton X-100 in 5% blocking buffer
(with blocking serum in which the secondary antibody was raised)
and subsequently used for immunolabeling with anti-CD31 anti-
bodies to detect blood vessels, Alexa-488-conjugated phalloidin,
and anti-b-galactosidase antibody to confirm lacZ expression in the
RPE as a genotype control. The area of each CNV lesion (in lm2)
was measured using Zeiss AxioVision software and the average
CNV lesion size for each eye determined. The number of CNV
lesions for each eye was counted as well. Unbiased measurements
were performed without knowing the genotyping information at
the time of analysis. Subsequently results were assigned to the
genotypes. The differences between age-matched mouse strains
were determined. P-values were calculated with a two-tailed
unpaired Student’s t-test. Average CNV lesion number and CNV
size per mouse are shown on a scatter plot (Prism 6.0b,
GraphPad) (Fig 8A and B). In addition, average CNV lesion area
values were log-transformed and CNV lesion number values were
root-square-transformed and P-values calculated separately
(Appendix Fig S3A and B).
RT–PCR and semiquantitative RT–PCR
To determine VEGF-A isoform and receptor expression, RNA was
isolated from the lens and RPE/choroid with TRIzol reagent (Life
Technologies). cDNA was obtained using the Transcriptor First
Strand Synthesis Kit utilizing hexamer primers (Roche). cDNA was
used to amplify VEGF-A isoforms and Flk1 and Flt1, and the PCR
product was loaded on a 3% agarose gel. For gene expression stud-
ies, semiquantitative RT–PCR was performed using a LightCycler
480 system with the LightCycler 480 SYBR Green I master mix
(Roche Applied Science, Indianapolis, IN). Primers for mouse 36B4
were used as normalization control. Concentrations were deter-
mined using a standard dilution curve. Semiquantitative RT-PCR
experiments for all samples were performed in triplicate with n = 7
mice/experimental group. Primers for RT–PCR and semiquantitative
RT–PCR are listed in Appendix Table S1.
Measurements of serum 4-HNE and of lens reduced
glutathione levels
We measured 4-HNE adducts (4-hydroxynonenal) in serum of mice,
a byproduct of lipid peroxidation during oxidative stress, using a
highly sensitive competitive ELISA according to the manufacturer’s
instructions (CellBiolabs). Reduced glutathione (the major antioxi-
dant in the lens) in lens lysates was determined with a HT
Glutathione Assay kit (Trevigen), according to the manufacturer’s
instructions. N = 7 mice/experimental group (two independent
experiments).
Analysis of cataract formation
Eyes were analyzed with a slit-lamp microscope. Cataract maturity
was classified according to the extent of morphological opacification
of the lens in vivo. Mild opacification of the lens that still allowed a
proper fundus examination was classified as grade 1, while
increased opacification that restricted a full fundus examination was
classified as grade 2. Complete opacification of the lens with leuko-
coria (white pupil) represented fully matured cataracts and were
classified as grade 3 cataracts.
Ratio (in %) of mice with cataracts per total mice in each age
group is shown in the graphs (Fig 3A and B).
Laser-induced CNV model and experimental treatments
Eyes of male 8-week-old C57BL/6J mice were exposed to laser
photocoagulation for the induction of experimental CNV after eyes
had been dilated with 1% tropicamide (n = 15 mice/experimental
group). Laser photocoagulation was performed using a 532-nm laser
(Visulas 532S; Carl Zeiss Meditec, Dublin, Ireland). Lesions were
induced using a power of 120 mW, a spot size of 100 lm, and a
duration of 100 ms. Eyes were assessed 7 days after laser treatment.
The size of CNV lesions was measured in choroidal flat mounts.
The eyes were enucleated and fixed in 4% paraformaldehyde over-
night at 4°C. The anterior segment, the lens, and the retina were
removed, and the RPE/choroid tissue (posterior eye) was treated
with 0.5% Triton X-100 in 5% blocking buffer (with blocking serum
in which the secondary antibody was raised) and subsequently used
for immunolabeling. The following antibodies were used for whole
mount immunolabeling of the RPE/choroid tissue: (i) anti-CD31
antibodies (rat anti-mouse CD31 (MEC13.3, BD PharMingen)) to
detect blood vessels (Alexa Fluor-488 secondary antibody), (ii) anti–
smooth muscle actin (SMA) antibodies [mouse monoclonal SMA-Cy3
ª 2016 The Author EMBO Molecular Medicine Vol 8 | No 3 | 2016
Alexander G Marneros Role of VEGF-A in aging diseases of the eye EMBO Molecular Medicine
227
conjugate (clone 1A4, Sigma)], and (iii) Alexa-647-conjugated rat
anti-mouse F4/80 (clone BM8, Biolegend) to detect macrophages.
Choroidal flat mounts were analyzed by epifluorescence microscopy
using a Zeiss microscope (Carl Zeiss Microscopy, Jena, Germany) or
with a Nikon confocal microscope (Nikon Instruments Inc, Melville,
NY). Images were obtained with a 20× objective. CNV lesions were
measured using Zeiss AxioVision software version 4.8.2. Average
CNV size was determined for each mouse, and differences between
mouse groups were assessed by a two-tailed unpaired Student’s t-test.
P-values < 0.05 were considered to be statistically significant. Exclu-
sion criteria for CNV lesions were the formation of a retinal plug and
abnormally large CNV lesions that formed over large choroidal
vessels. CD31+ CNV lesion area was measured.
Experimental mouse groups were treated with the caspase-1
inhibitor Ac-YVAD-cmk (25 lg/mouse caspase-1 inhibitor II in
DMSO, Calbiochem) subcutaneously daily from the day of the laser
treatment. This dose and administration regimen has been shown to
inhibit caspase-1-mediated activities in mice (Lalor et al, 2011).
Control mice received the same daily volume of DMSO subcuta-
neously. Ac-YVAD-cmk is a selective irreversible inhibitor of
caspase-1 and has been shown to inhibit inflammasome activation.
Additional experimental groups were treated with either the
neutralizing anti-TLR2 antibody (clone T2.5, eBioscience) or an
isotype-matched IgG control antibody (2 lg/mouse intravenously
per tail vein injections on the day of the laser treatment and on
day 2 and day 4 after laser treatment). This treatment regimen has
previously been shown to inhibit TLR2 activity in mice (Wang
et al, 2014).
Electroretinograms (ERGs), fundus imaging, and optical
coherence tomography (OCT)
Age-matched 21-month-old experimental mouse groups were used
for ERG experiments. ERG recordings of both left and right eyes of
each mouse were obtained. Eyes with cataracts were excluded from
the analysis to distinguish retinal abnormalities from the effects of
cataracts on ERG recordings.
Following overnight dark adaptation, the animals were prepared
for ERG recordings under dim red light. While under anesthesia with
a mixture of ketamine (120 mg/kg i.p.) and xylazine (20 mg/kg
i.p.), the animal body temperature was maintained at 38°C, using
an electrical heated platform, and the pupils of the mice were
dilated using 1% tropicamide and 2.5% phenylephrine hydrochlo-
ride applied on the corneal surface. One drop of GenTeal eye gel
(corneal lubricant) was applied to the cornea to prevent dehydration
and to allow electrical contact with the recording electrode. A 25-
gauge platinum needle, inserted subcutaneously in the forehead,
served as the reference electrode, while a needle inserted subcuta-
neously near the tail served as the ground electrode. A series of
flash intensities were produced by a Ganzfeld color dome controlled
by the Diagnosys Espion3 (Diagnosys LLC) to test both scotopic and
photopic responses.
Dark-adapted ERG recordings (to assess mainly rod function) are
shown for measurements obtained after 4-ms light flashes (white
light 6,500 K; 6 sweeps; 55,100-ms intersweep delay) with a light
intensity of 24.1 cd.s/m2.
Light-adapted ERG recordings (to assess mainly cone function)
are shown for measurements obtained after 7 min of light adaptation
(white light 6,500 K, 30 cd/m2) with a light intensity of 102.4 cd.s/m2
(25 sweeps, 1 Hz frequency) produced by a xenon light source. For
each experimental mouse group, average values for a- and b-waves
were calculated and P-values are shown using a two-tailed unpaired
Student’s t-test.
Fundus autofluorescence assessment, fundus imaging, and
OCTs were performed as previously described (Ablonczy et al,
2014).
VEGF-A ELISA
Lenses from age-matched VEGF-Ahyper mice and control littermate
mice were used for VEGF-A ELISA measurements. Freshly dissected
lenses were lysed in NP-40 lysis buffer (Life Technologies) with
1 mM PMSF and protease inhibitor cocktail (Complete, Roche)
using the Qiagen TissueLyser II. After centrifugation, the super-
natant was assayed for VEGF-A. Supernatant VEGF-A levels were
determined using a mouse VEGF-A ELISA kit according to the
manufacturer’s instructions (R&D Systems) and values shown are
pg VEGF-A/ml lysate. Statistical significance was determined with a
two-tailed unpaired Student’s t-test.
Statistics
An unpaired two-tailed Student’s t-test was used for statistical
analyses. P-values < 0.05 were considered to be statistically
significant. P-values *< 0.05, **< 0.01, ***< 0.001, ****< 0.0001.
Expanded View for this article is available online.
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The paper explained
Problem
There are currently no effective therapies for “dry” AMD, and only a
subset of patients with “wet” AMD respond to anti-VEGF-A therapies.
Approaches to prevent the formation of senile cataracts are also very
limited. Thus, novel therapeutic targets for these age-related eye
diseases are urgently needed.
Results
We show that an increase in VEGF-A is sufficient to induce multiple
common aging pathologies of the eye, resembling “wet” and “dry”
AMD, as well as cataracts. Targeting components of the NLRP3
inflammasome strongly inhibits these aging eye diseases from
developing. Moreover, we identify a critical role of Flk1 signaling in
the RPE and of TLR2 for the manifestation of “wet” AMD-like
pathologies.
Impact
Our findings suggest common pathomechanisms involved in age-
related cataract formation and in the development of both forms of
AMD, and identify novel molecular targets for a broad therapeutic
approach to simultaneously inhibit these distinct common eye
diseases.
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